Table 1.
Clinical, hematologic, and cytogenetic characteristics of the MDS patients
| Age | Sex | Diagnosis | Screening | Karyotype [no. metaphases with aberration] | Clinical outcome | Total cycles | Duration of therapy (months) | Time to first response (cycles) | Duration of response (months) | Survival (months) | Time to AML Evolution (months) | Cause of death | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| WHO | WPSS | |||||||||||||
| a1 | 67 | M | RAEB-2 | VERY- HIGH | 25/03/2013 | COMPLEX | SD | 10 | 10 | NA | NA | 14 | 8 | AML |
| a2 | 67 | F | RAEB-2 | HIGH | 02/04/2013 | 46, XX | CR | 30 | 28 | 6 | 24 | 35 | 28 | OVARIAN CANCER |
| a3 | 71 | M | RAEB-2 | HIGH | 29/04/2013 | 47, XY, +8 [8] | mCR | 38 | 36 | 4 | 10 | 41 | 36 | AML, INFECTION |
| a4 | 76 | F | RAEB-2 | HIGH | 13/05/2013 | 46, XX [1] | HI | 8 | 8 | 4 | 3 | 12 | 9 | AML, CACHEXIA |
| a5 | 68 | M | RAEB-1 | HIGH | 13/05/2013 | COMPLEX | SD | 9 | 9 | NA | NA | 14 | PNEUMONIA, CARDIAC FAILURE | |
| a6 | 67 | M | RAEB-2 | HIGH | 23/05/2013 | 46, XY | PR | 10 | 10 | 2 | 5 | 30 | 10 | AML |
| a7 | 72 | M | RAEB-1 | HIGH | 26/06/2013 | 46, XY, del(7)(q22;34) [20]; del(7q31) [18] | SD | 8 | 8 | NA | NA | 22 | 20 | CEREBRAL HEMORRHAGE |
| 8 | 82 | M | RAEB-2 | HIGH | 28/06/2013 | 46, XY | CR | 41 | 42 | 2 | 40 | 42 | ||
| 9 | 67 | F | RAEB-1 | HIGH | 01/07/2013 | 47, XX, +8 | HI + mCR | 12 | 18 | 2 (mCR); 5 (HI) | 8 (HI); 16 (mCR) | 42 | ||
| 10 | 73 | F | RAEB-1 | INT | 10/07/2013 | 45, X, del(X), del(20q) | HI + mCR | 38 | 42 | 3 (HI) + 4 (mCR) | 35 (HI); 34 (mCR) | 42 | ||
| a11 | 75 | F | RAEB-1 | HIGH | 10/07/2013 | 47, XX, +8 | HI | 20 | 21 | 1 | 19 | 28 | 21 | DISEASE PROGRESSION |
| 12 | 76 | M | RAEB-1 | INT | 22/07/2013 | 46, XY | HI + mCR | 8 | 8 | 1 | 5 (HI); 6 (mCR) | 38 | ||
| a13 | 74 | M | RAEB-2 | ND | 24/07/2013 | ND | NA | 1 | 1 | NA | NA | 2 | PNEUMONIA | |
| a14 | 78 | M | RAEB-2 | HIGH | 05/08/2013 | 46, XY | HI | 19 | 25 | 8 | 9 | 27 | 25 | AML |
| a15 | 72 | M | RAEB-2 | HIGH | 28/08/2013 | 46, XY, del(5), del(9) | NA | 2 | 3 | NA | NA | 12 | WORSENING OF CLINICAL CONDITIONS | |
| 16 | 70 | M | RAEB-2 | HIGH | 29/08/2013 | 46, XY | CR | 27 | 40 | 2 | 38 | 40 | ||
| a17 | 75 | F | RAEB-2 | HIGH | 03/09/2013 | 46, XX, t(2;15)(q23;q26) | DP | 2 | 2 | NA | NA | 5 | 2 | AML |
| a18 | 72 | F | RCMD- RS | HIGH | 09/09/2013 | COMPLEX | HI + mCR | 13 | 14 | 2 | 11 | 16 | 15 | AML, SEPSIS |
| a19 | 62 | M | RAEB-1 | HIGH | 17/09/2013 | 46, XY, del(7), +X, [18] | CR | 6 | 7 | 1 | 5 | 14 | CARDIAC EVENT | |
| a20 | 70 | F | RAEB-2 | HIGH | 23/09/2013 | 46, XX | NA | 2 | 2 | NA | NA | 2 | COPD | |
| a21 | 82 | M | RCMD | HIGH | 23/09/2013 | 47, XY, +8, −9,+3mar | HI | 20 | 28 | 6 | 18 | 28 | RESPIRATORY FAILURE | |
| 22 | 82 | M | RAEB-2 | HIGH | 25/09/2013 | 46, XY, del(20q) | CR | 36 | 39 | 1 | 38 | 39 | ||
| a23 | 68 | M | RCMD | HIGH | 03/10/2013 | 45, XY, del(7) | HI | 3 | 3 | 1 | 2 | 3 | SUDDEN DEATH | |
| 24 | 75 | M | RAEB-2 | VERY- HIGH | 28/10/2013 | 45, XY, del(7), del(20)(q11)[3] / 46, XY [17] | NA | 1 | 1 | NA | NA | 35 | ||
| a25 | 66 | F | RAEB-2 | HIGH | 15/10/2013 | 46, XX | SD | 8 | 8 | NA | NA | 14 | 14 | AML |
| a26 | 77 | M | RAEB-2 | HIGH | 30/10/2013 | 46, XXYY [5] | NA | 1 | 1 | NA | NA | 5 | HEART FAILURE | |
| a27 | 48 | F | RAEB-2 | VERY- HIGH | 06/11/2013 | 47, XY, + 8 | CR | 16 | 15 | 2 | 11 | 26 | DISEASE PROGRESSION | |
| a28 | 64 | F | RAEB-1 | INT | 06/11/2013 | 46, XX | HI | 10 | 10 | 5 | 3 | 12 | PULMONARY CARCINOMA | |
| a29 | 79 | F | RAEB-2 | ND | 13/11/2013 | ND | NA | 2 | 2 | NA | NA | 3 | HEART ATTACK | |
| a30 | 66 | M | RAEB-2 | VERY- HIGH | 15/11/2013 | 47, XY, +8 | HI | 9 | 9 | 3 | 4 | 10 | WORSENING OF CLINICAL CONDITIONS | |
| a31 | 75 | F | RAEB-2 | HIGH | 22/11/2013 | 46, XX | HI | 10 | 10 | 2 | 5 | 11 | 11 | AML |
| a32 | 83 | M | RAEB-2 | HIGH | 04/02/2014 | 47, XX, +8 [5] | SD | 6 | 6 | NA | NA | 11 | 9 | AML |
| a33 | 71 | F | RAEB-2 | VERY- HIGH | 17/02/2014 | COMPLEX | CR | 7 | 7 | 2 | 5 | 12 | 9 | AML, SEPSIS |
| a34 | 66 | F | RAEB-2 | VERY- HIGH | 10/03/2014 | COMPLEX | DP | 1 | 1 | NA | NA | 2 | 1 | AML, INFECTION |
| 35 | 72 | M | RAEB-1 | VERY- HIGH | 14/04/2014 | COMPLEX | HI + mCR | 11 | 11 | 4 (HI + mCR) | 6 (HI) | 32 | ||
| a36 | 69 | M | RAEB-2 | HIGH | 19/05/2014 | 46, XY | mCR | 6 | 6 | 2 | 3 | 16 | 13 | AML |
| 37 | 70 | M | RAEB-1 | HIGH | 19/05/2014 | 46, XY, del(7q31) | SD | 7 | 9 | NA | NA | 31 | ||
| a38 | 77 | F | RAEB-2 | VERY- HIGH | 19/05/2014 | COMPLEX | NA | 2 | 4 | NA | NA | 4 | BILATERAL PNEUMONIA | |
| a39 | 82 | F | RAEB-1 | VERY- HIGH | 04/08/2014 | COMPLEX | NA | 1 | 2 | NA | NA | 7 | 3 | AML |
| a40 | 80 | M | RAEB-2 | VERY- HIGH | 15/09/2014 | 46, XY, t(9,17) (p36;q23) [19] | NA | 2 | 2 | NA | NA | 2 | CACHEXIA, HEPATIC FAILURE | |
| a41 | 78 | M | RAEB-2 | HIGH | 19/08/2014 | 46, XY | HI + mCR | 17 | 16 | 2 (HI); 2 (mCR) | 14 (HI); 14 (mCR) | 17 | UNKNOWN | |
| 42 | 74 | M | RAEB-2 | VERY- HIGH | 18/08/2014 | 46, XY, del(7) [1] | CR | 26 | 28 | 1 | 27 | 28 | ||
| a43 | 66 | M | RAEB-2 | HIGH | 20/10/2014 | 46, XY | NA | 2 | 2 | NA | NA | 7 | RESPIRATORY FAILURE | |
| 44 | 76 | M | RAEB-2 | HIGH | 09/12/2014 | 46, XY | mCR | 22 | 25 | 4 | 21 | 25 | ||
WHO World Health Organization; WPSS WHO Prognostic Scoring System; RAEB refractory anemia with excess of blasts; RCMD refractory cytopenia with multilineage dysplasia; RCMD-RS refractory cytopenia with multilineage dysplasia and ringed sideroblasts; VERY-HIGH very-high-risk; HIGH high-risk; INT intermediate risk; CR complete remission; mCR marrow complete remission; PR partial remission; HI hematologic improvement; SD stable disease; DP disease progression; AML acute myeloid leukemia; COPD chronic obstructive pulmonary disease
aPatients deceased during follow-up